Category Archives: Events

Latest From Events

Biotech Investors, Emerging Companies Bullish On 2014

Jim Greenwood

The 16th BIO CEO & Investor Conference is off to a great start. This event has truly grown into a must attend for emerging companies and investors. This year, we have more than 1,300 participants, including more than 850 investors. In addition, we have helped to set up more than 1,700 partnering meetings for participants over the course of the conference. Our world-class partnering system, and the opportunity to hear from key industry leaders, is Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , ,

Buy Side Investors Bullish Ahead of 2014 BIO CEO & Investor Conference

CEO2014_blog copy

2013 was a record year for the biotech sector, with the NASDAQ Biotechnology Index hitting record highs again and again, ending the year up over 60% — beating the S&P 500 more than two-fold.   But what can we expect for 2014? That will be the topic of discussion at our opening plenary panel at next week’s BIO CEO & Investor Conference, taking place Monday and Tuesday, February 10-11 in New York. To help spur Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

2013 Novel Drug Approvals

Therapeutic-Indications-with-Novel-Drug-Approvals-in-2013-115x76

The FDA approved 24 novel drugs last year by our count, in line with average approvals for the last ten years but down from the decade-high approvals seen in 2012. Our count is a bit lower than the FDA’s count of 27 new approvals, because we did not include imaging agents like Navidea’s Lymphoseek, or reformulations like J&J’s Simponi Aria. 2013 was the first year the breakthrough-designated therapies were approved, with three breakthrough therapies approved: Gilead’s Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

More than a Quarter of 2013 US-Based Biotech IPOs Call California Home

BIO CONVENTION LOGO_VERTICAL_D_CMYK

And of those 39 US-based biotech companies, five of them are from San Diego, highlighting the region’s growing importance as hub for the biotech and life science industries. According to a recently authored BIO article in the Union Tribune San Diego, there are several reasons at play for the strong public offerings – enactment of the JOBS Act, an eager investor market and increasing regulatory transparency resulting from PDUFA V. As powerful as the JOBS Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

BIO CEO Company Snapshot: Conatus Pharmaceuticals

Conatus-Pharma

The Company Snapshots have returned for our next One-on-One Partnering event, the BIO CEO & Investor Conference, taking place in New York City this February. The companies that will be profiled in these snapshots will all be presenting at the event, and we hope this provides the opportunity to learn more about them, and catch up on what’s new. What is your company’s lead product or technology? Conatus’s lead product is emricasan, a first-in-class oral Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , ,